CytoMed Therapeutics (GDTC) announces it has successfully expanded clinical-scale natural killer, NK, cells from cord blood units that have been cryopreserved for more than a decade. This sets the impetus for establishing a new business platform to generate additional revenue streams and future growth. In light of this recent development, the company is re-organizing and streamlining its group structure to create a new cord blood-derived biotech under LongevityBank which owns 100% of its licensed cord blood bank, IPSC Depository.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDTC:
- CytoMed Therapeutics Launches ATM Offering Program to Boost Growth
- Cytomed Therapeutics announces $4.3M at-the-market offering program
- CytoMed Therapeutics Advances ANGELICA Trial to Dose Level 2
- Cytomed Therapeutics completes dose level 1 of ANGELICA trial
- CytoMed Therapeutics Issues Shares to Executives as Compensation